drugset / Trial / NCT04418427
ADVM-022 Intravitreal Gene Therapy for DME
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2, Multi-Center, Randomized, Double-Masked\*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema \[INFINITY\]
Timeline
- Start
- 2020-05-28
- Primary completion
- 2022-11-22
- Completion
- 2023-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADVM-022 | Gene therapy (AAV / viral vector) | 2e+11 vg | Intravitreal |
| Subject | ADVM-022 | Gene therapy (AAV / viral vector) | 6e+11 vg | Intravitreal |
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |